• Je něco špatně v tomto záznamu ?

The effect of ω-3 polyunsaturated fatty acids on the liver lipidome, proteome and bile acid profile: parenteral versus enteral administration

K. Bechynska, N. Daskova, N. Vrzackova, K. Harant, M. Heczková, K. Podzimkova, M. Bratova, H. Dankova, Z. Berkova, V. Kosek, J. Zelenka, J. Hajslova, R. Sedlacek, J. Suttnar, A. Hlavackova, L. Bartonova, M. Cahova,

. 2019 ; 9 (1) : 19097. [pub] 20191213

Jazyk angličtina Země Velká Británie

Typ dokumentu srovnávací studie, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20028708

Parenteral nutrition (PN) is often associated with the deterioration of liver functions (PNALD). Omega-3 polyunsaturated fatty acids (PUFA) were reported to alleviate PNALD but the underlying mechanisms have not been fully unraveled yet. Using omics´ approach, we determined serum and liver lipidome, liver proteome, and liver bile acid profile as well as markers of inflammation and oxidative stress in rats administered either ω-6 PUFA based lipid emulsion (Intralipid) or ω-6/ω-3 PUFA blend (Intralipid/Omegaven) via the enteral or parenteral route. In general, we found that enteral administration of both lipid emulsions has less impact on the liver than the parenteral route. Compared with parenterally administered Intralipid, PN administration of ω-3 PUFA was associated with 1. increased content of eicosapentaenoic (EPA)- and docosahexaenoic (DHA) acids-containing lipid species; 2. higher abundance of CYP4A isoenzymes capable of bioactive lipid synthesis and the increased content of their potential products (oxidized EPA and DHA); 3. downregulation of enzymes involved CYP450 drug metabolism what may represent an adaptive mechanism counteracting the potential negative effects (enhanced ROS production) of PUFA metabolism; 4. normalized anti-oxidative capacity and 5. physiological BAs spectrum. All these findings may contribute to the explanation of ω-3 PUFA protective effects in the context of PN.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20028708
003      
CZ-PrNML
005      
20210208142243.0
007      
ta
008      
210105s2019 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41598-019-54225-8 $2 doi
035    __
$a (PubMed)31836843
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Bechynska, Kamila $u University of Chemistry and Technology, Prague, Czechia.
245    14
$a The effect of ω-3 polyunsaturated fatty acids on the liver lipidome, proteome and bile acid profile: parenteral versus enteral administration / $c K. Bechynska, N. Daskova, N. Vrzackova, K. Harant, M. Heczková, K. Podzimkova, M. Bratova, H. Dankova, Z. Berkova, V. Kosek, J. Zelenka, J. Hajslova, R. Sedlacek, J. Suttnar, A. Hlavackova, L. Bartonova, M. Cahova,
520    9_
$a Parenteral nutrition (PN) is often associated with the deterioration of liver functions (PNALD). Omega-3 polyunsaturated fatty acids (PUFA) were reported to alleviate PNALD but the underlying mechanisms have not been fully unraveled yet. Using omics´ approach, we determined serum and liver lipidome, liver proteome, and liver bile acid profile as well as markers of inflammation and oxidative stress in rats administered either ω-6 PUFA based lipid emulsion (Intralipid) or ω-6/ω-3 PUFA blend (Intralipid/Omegaven) via the enteral or parenteral route. In general, we found that enteral administration of both lipid emulsions has less impact on the liver than the parenteral route. Compared with parenterally administered Intralipid, PN administration of ω-3 PUFA was associated with 1. increased content of eicosapentaenoic (EPA)- and docosahexaenoic (DHA) acids-containing lipid species; 2. higher abundance of CYP4A isoenzymes capable of bioactive lipid synthesis and the increased content of their potential products (oxidized EPA and DHA); 3. downregulation of enzymes involved CYP450 drug metabolism what may represent an adaptive mechanism counteracting the potential negative effects (enhanced ROS production) of PUFA metabolism; 4. normalized anti-oxidative capacity and 5. physiological BAs spectrum. All these findings may contribute to the explanation of ω-3 PUFA protective effects in the context of PN.
650    _2
$a zvířata $7 D000818
650    _2
$a žlučové kyseliny a soli $x analýza $7 D001647
650    _2
$a kyseliny dokosahexaenové $x chemie $7 D004281
650    _2
$a kyselina eikosapentaenová $x chemie $7 D015118
650    _2
$a emulze $7 D004655
650    _2
$a enterální výživa $x metody $7 D004750
650    _2
$a kyseliny mastné omega-3 $x chemie $7 D015525
650    _2
$a nenasycené mastné kyseliny $x metabolismus $7 D005231
650    _2
$a rybí oleje $7 D005395
650    _2
$a zánět $7 D007249
650    _2
$a lipidomika $7 D000081362
650    _2
$a lipidy $x chemie $7 D008055
650    _2
$a játra $x metabolismus $7 D008099
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a malondialdehyd $x metabolismus $7 D008315
650    _2
$a metabolomika $7 D055432
650    _2
$a oxidační stres $7 D018384
650    _2
$a kyslík $x metabolismus $7 D010100
650    _2
$a parenterální výživa $x metody $7 D010288
650    _2
$a fosfolipidy $7 D010743
650    _2
$a proteom $x metabolismus $7 D020543
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a potkani Wistar $7 D017208
650    _2
$a reaktivní formy kyslíku $x metabolismus $7 D017382
650    _2
$a sójový olej $7 D013024
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Ďásková, Nikola $u Center of Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czechia. $7 xx0256836
700    1_
$a Vrzackova, Nikola $u University of Chemistry and Technology, Prague, Czechia.
700    1_
$a Harant, Karel $u Proteomics Core Facility, BIOCEV, Faculty of Science Charles University, Prague, Czechia.
700    1_
$a Heczková, Marie $u Center of Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czechia.
700    1_
$a Podzimkova, Katerina $u Czech Centre for Phenogenomics, Vestec, Czechia.
700    1_
$a Bratova, Miriam $u Center of Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czechia.
700    1_
$a Dankova, Helena $u Center of Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czechia.
700    1_
$a Berkova, Zuzana $u Center of Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czechia.
700    1_
$a Kosek, Vit $u University of Chemistry and Technology, Prague, Czechia.
700    1_
$a Zelenka, Jaroslav $u University of Chemistry and Technology, Prague, Czechia.
700    1_
$a Hajslova, Jana $u University of Chemistry and Technology, Prague, Czechia.
700    1_
$a Sedlacek, Radislav $u Czech Centre for Phenogenomics, Vestec, Czechia.
700    1_
$a Suttnar, Jiri $u Institute of Hematology and Blood Transfusion, Prague, Czechia.
700    1_
$a Hlavackova, Alzbeta $u Institute of Hematology and Blood Transfusion, Prague, Czechia.
700    1_
$a Bartonova, Lenka $u Department of Pathology, Institute for Clinical and Experimental Medicine, Prague, Czechia. First Faculty of Medicine, Charles University, Prague, Czechia.
700    1_
$a Cahova, Monika $u Center of Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czechia. monika.cahova@ikem.cz.
773    0_
$w MED00182195 $t Scientific reports $x 2045-2322 $g Roč. 9, č. 1 (2019), s. 19097
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31836843 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20210105 $b ABA008
991    __
$a 20210208142242 $b ABA008
999    __
$a ok $b bmc $g 1609043 $s 1119888
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 9 $c 1 $d 19097 $e 20191213 $i 2045-2322 $m Scientific reports $n Sci Rep $x MED00182195
LZP    __
$a Pubmed-20210105

Najít záznam

Citační ukazatele

Možnosti archivace